87 related articles for article (PubMed ID: 11238875)
1. Regression of a murine gammaherpesvirus 68-positive b-cell lymphoma mediated by CD4 T lymphocytes.
Robertson KA; Usherwood EJ; Nash AA
J Virol; 2001 Apr; 75(7):3480-2. PubMed ID: 11238875
[TBL] [Abstract][Full Text] [Related]
2. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
3. Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells.
Cheadle EJ; Hawkins RE; Batha H; Rothwell DG; Ashton G; Gilham DE
J Immunother; 2009 Apr; 32(3):207-18. PubMed ID: 19242379
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells.
Song W; Levy R
Cancer Res; 2005 Jul; 65(13):5958-64. PubMed ID: 15994975
[TBL] [Abstract][Full Text] [Related]
5. An optimized CD4 T-cell response can control productive and latent gammaherpesvirus infection.
Sparks-Thissen RL; Braaten DC; Kreher S; Speck SH; Virgin HW
J Virol; 2004 Jul; 78(13):6827-35. PubMed ID: 15194758
[TBL] [Abstract][Full Text] [Related]
6. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes.
Margalit M; Shibolet O; Klein A; Elinav E; Alper R; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2005 Jun; 115(3):443-9. PubMed ID: 15688366
[TBL] [Abstract][Full Text] [Related]
7. Targeting high-grade B cell lymphoma with CD19-specific T cells.
Lehmann FM; Maurberger A; Feicht S; Helm F; Ladinig C; Kieback E; Uckert W; Kammertöns T; Kremmer E; Mautner J; Gerbitz A; Bornkamm GW
Int J Cancer; 2014 Sep; 135(5):1153-64. PubMed ID: 24500882
[TBL] [Abstract][Full Text] [Related]
8. Murine gammaherpesvirus-induced splenomegaly: a critical role for CD4 T cells.
Usherwood EJ; Ross AJ; Allen DJ; Nash AA
J Gen Virol; 1996 Apr; 77 ( Pt 4)():627-30. PubMed ID: 8627250
[TBL] [Abstract][Full Text] [Related]
9. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
10. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Bristol JA; Schlom J; Abrams SI
Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
[TBL] [Abstract][Full Text] [Related]
11. Study on the roles of CD4+ and CD8+ T cells in the expression of host resistance to Mycobacterium leprae infection induced in athymic nude mice.
Maw WW; Tomioka H; Sato K; Yamada Y; Saito H
Int J Lepr Other Mycobact Dis; 1995 Dec; 63(4):539-45. PubMed ID: 8642217
[TBL] [Abstract][Full Text] [Related]
12. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
13. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of murine cytomegalovirus-immune lymph node cells prevents retinitis in T-cell-depleted mice.
Lu Y; Bigger JE; Thomas CA; Atherton SS
Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):301-10. PubMed ID: 9040462
[TBL] [Abstract][Full Text] [Related]
15. Requirement for CD4+ T cells in V beta 4+CD8+ T cell activation associated with latent murine gammaherpesvirus infection.
Flaño E; Woodland DL; Blackman MA
J Immunol; 1999 Sep; 163(6):3403-8. PubMed ID: 10477611
[TBL] [Abstract][Full Text] [Related]
16. Induction of CD4(+) and CD8(+) anti-tumor effector T cell responses by bacteria mediated tumor therapy.
Stern C; Kasnitz N; Kocijancic D; Trittel S; Riese P; Guzman CA; Leschner S; Weiss S
Int J Cancer; 2015 Oct; 137(8):2019-28. PubMed ID: 25868911
[TBL] [Abstract][Full Text] [Related]
17. Immunological control of a murine gammaherpesvirus independent of CD8+ T cells.
Stevenson PG; Cardin RD; Christensen JP; Doherty PC
J Gen Virol; 1999 Feb; 80 ( Pt 2)():477-483. PubMed ID: 10073710
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
[TBL] [Abstract][Full Text] [Related]
19. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
[TBL] [Abstract][Full Text] [Related]
20. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
